Enanta Pharmaceuticals (STU:9EP) NonCurrent Deferred Liabilities: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9EP Enanta Pharmaceuticals Inc STU:9EP
59 GF Score
Price €10.90
GF Value €7.61
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals NonCurrent Deferred Liabilities?

Enanta Pharmaceuticals STU:9EP -1.80% 59 NonCurrent Deferred Liabilities is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:9EP with a GF Score™ of 59/100 and a GF Value™ of €7.61 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Enanta Pharmaceuticals's non-current deferred liabilities for the quarter that ended in Mar. 2026 was €0.00 Mil.

Enanta Pharmaceuticals NonCurrent Deferred Liabilities Related Terms

Enanta Pharmaceuticals NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Enanta Pharmaceuticals's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals NonCurrent Deferred Liabilities Chart

Enanta Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Enanta Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:9EP
59GF Score
Enanta Pharmaceuticals Inc STU:9EP
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €0.00 Mil mean?
Enanta Pharmaceuticals (STU:9EP) has a NonCurrent Deferred Liabilities of €0.00 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Enanta Pharmaceuticals and its competitors.
Is Enanta Pharmaceuticals' NonCurrent Deferred Liabilities too high?
Enanta Pharmaceuticals' current NonCurrent Deferred Liabilities is €0.00 Mil. Overall, Enanta Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' NonCurrent Deferred Liabilities compare to CMPX and CCCC?
Enanta Pharmaceuticals' NonCurrent Deferred Liabilities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Enanta Pharmaceuticals and its competitors. Enanta Pharmaceuticals's current NonCurrent Deferred Liabilities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (STU:9EP) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.61, compared to a current price of €10.90 — trading 43.2% above its estimated fair value. The current NonCurrent Deferred Liabilities is €0.00 Mil. Enanta Pharmaceuticals' overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Enanta Pharmaceuticals (STU:9EP), the current NonCurrent Deferred Liabilities is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enanta Pharmaceuticals (STU:9EP) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of €10.90 is trading 43.2% above its estimated GF Value™ of €7.61. GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:9EP:

  • NonCurrent Deferred Liabilities: €0.00 Mil
  • GF Value™: €7.61 vs. price of €10.90 (43.2% above fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the STU:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enanta Pharmaceuticals Business Description

Other Exchanges ENTA:USA9EP:Germany
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
59GF Score

Get the complete analysis for STU:9EP

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.90
Price
€7.61
GF Value